Familial Mediterranean fever

OMass’s OdyssION™ Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D

Retrieved on: 
星期一, 二月 28, 2022
Therapy, Muscle, Stomach, GSDMD, Degenerative disease, Pain, Louis-Jeantet Prize for Medicine, Mass, Noise, Familial Mediterranean fever, Lipid, Fever, Biology, Heart, Drug discovery, Medicine, Joint, Mass spectrometry, G protein-coupled receptor, Membrane protein, Ecosystem, Technology, Patent, CEO, Pharmaceutical industry, Vaccine, Fine chemical, Chemistry

OMasss OdyssION Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D

Key Points: 
  • OMasss OdyssION Drug Discovery Platform Makes Progress in Drugging the Undruggable, including Gasdermin D
    Oxford, United Kingdom 28 February 2022 OMass Therapeutics (OMass or the Company), a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to provide an update on its proprietary drug discovery platform, OdyssION and its progress in identifying novel medicines against intractable or inadequately drugged membrane and complex-bound proteins.
  • Early data and progress in its gasdermin D program underline the power of the platform.
  • The OdyssION platform allows OMass to interrogate how a protein interacts with its native ecosystem, separate from the confounding complexity of the cell.
  • However, due to the power of the OdyssION platform, OMass has been able to identify a functional hit series.

Health Canada approval of low-dose colchicine for cardiovascular disease based on the COLCOT study

Retrieved on: 
星期五, 八月 27, 2021
People, Montreal Heart Institute, Gout, Institute, Leadership, Knowledge, Systematic review, Research, Health, The New England Journal of Medicine, Cardiac arrest, Precision medicine, Safety, Risk, Pericarditis, Myocardial infarction, Compliance, Death, Neurology, Clinical trial, Â, Meta-analysis, Cardiovascular disease, Patient, Stroke, Gerard van Opstal, Familial Mediterranean fever, Hospital, Cardiology, Colchicine, Moyamoya disease, Veni, vidi, vici, Tablet, Angina, Health Canada, MHI, Coronary artery disease, GLOBE, Physician, USS Waters (DD-115), SM, Advertising, Dietary supplement, Medical device, Pharmaceutical industry, Coffee

Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)s COLCOT clinical trial.

Key Points: 
  • Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)s COLCOT clinical trial.
  • We are pleased that Health Canada has recognized the efficacy and safety of low-dose colchicine for the prevention of atherothrombotic events.
  • Cardiovascular disease is one of the leading causes of death and hospitalization in Canada.
  • Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).

Nearly Half of Americans Surveyed Willing to Consider Participating in Generic Drug Trials for COVID-19 Treatments Despite Testing Notification Delays up to Six Days

Retrieved on: 
星期日, 八月 23, 2020
Medical specialties, Health, Clinical medicine, RTT, Arthritis, Rheumatology, Alkaloids, Colchicine, Pericarditis, Gout, Clinical trial, Familial Mediterranean fever

Each of those studies concluded that we need quality, robust clinical trials like COLCORONA to definitively change clinical practice for colchicine usage."

Key Points: 
  • Each of those studies concluded that we need quality, robust clinical trials like COLCORONA to definitively change clinical practice for colchicine usage."
  • Non-hospitalized patients over 40 years old, diagnosed with COVID-19, can participate for free by calling the hotline at 1-877-536-6837.
  • Colchicine is a generic, orally administered anti-inflammatory medication that is currently indicated for the management of pericarditis, gout, and familial Mediterranean fever.
  • It has specific expertise in precision medicine, low-cost high-quality clinical trials, and drug repurposing.